Clinical Trial Update: Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) [Phase 2]

View source ↗

Summary

A Phase 2 trial of elotuzumab for IgG4-related disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• Empliciti (elotuzumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: IgG4 Related Disease, IgG4-RD | Phase 2 | Status: TERMINATED | Results posted: 2025-02-25